Pseudouridine Synthase 1-Targeted Therapy Activates Antiviral Immunity to Boost Cancer Immunotherapy

Researchers identified pseudouridine synthase 1 (PUS1) as a key driver of tumor immune evasion. They found that PUS1 is aberrantly overexpressed in tumors and correlates with tumor malignant progression.